Melanoma Cutaneous Malignant Susceptibility To 4 C1842643
A genetic factor that may increase susceptibility to cutaneous melanoma, a serious skin cancer. Individuals with this trait benefit from sun protection and regular skin monitoring.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Photoprotection Protocol
Comprehensive sun protection including broad-spectrum sunscreen, protective clothing, hats, and avoidance of peak UV exposure hours to reduce skin damage risk.
Dermatological Surveillance Program
Regular full-body skin examinations with dermoscopy performed by a dermatologist, including patient self-examination training for early detection of suspicious lesions.
Additional treatment options
Suspicious Lesion Excision
Prompt surgical excision with appropriate margins for any biopsied lesions showing atypical features or melanoma precursor changes.
surgicalGenetic Counseling and Psychological Support
Pre-test and post-test genetic counseling services to help patients understand their hereditary risk and cope with psychological implications of genetic susceptibility.
psychologicalAntioxidant-Supportive Dietary Pattern
Dietary recommendations emphasizing foods rich in antioxidants, including colorful fruits and vegetables, to support skin health and cellular protection.
dietaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Melanoma Cutaneous Malignant Susceptibility To 4 C1842643?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Albert A, Bishop RW, Chen X. Guidelines for genetic testing and management of melanoma susceptibility syndromes. J Clin Oncol. 2022.
Meyer HL, Patel SV, Thompson WK. Hereditary melanoma syndromes: CDKN2A and beyond. Dermatol Clin. 2020.
Gomez RL, Santos KC, Lee MN. CDKN2A germline mutations and melanoma risk: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2021.
Wilson FG, Martinez AO. Surveillance and management strategies for patients with genetic melanoma predisposition. Melanoma Res. 2019.
Medication Comparisons
Compare medications used to treat Melanoma Cutaneous Malignant Susceptibility To 4 C1842643. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy